The Economic Impact of Switching To Herceptin (TRASTUZUMAB) Biosimilar for The Treatment of Metastatic Breast Cancer From A UK Payer Perspective
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.157
https://www.valueinhealthjournal.com/article/S1098-3015(17)30491-6/fulltext
Title :
The Economic Impact of Switching To Herceptin (TRASTUZUMAB) Biosimilar for The Treatment of Metastatic Breast Cancer From A UK Payer Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30491-6&doi=10.1016/j.jval.2017.08.157
First page :
A425
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
141